Table 4. Base case results for all three scenarios.
| Trastuzumab | No trastuzumab | ||||||
|---|---|---|---|---|---|---|---|
| Costs | LYs | QALYs | Costs | LYs | QALYs | ||
| (95% CI) | (95% CI) | (95% CI) | (95% CI) | (95% CI) | (95% CI) | ||
| Real world scenario | |||||||
| Trastuzumab treatmenta | € 31,061 | € 0 | |||||
| (€29,241 - €32,950) | (€0 - €0) | ||||||
| Cardiac event / monitoring | € 448 | -0.016 | € 0 | -0.003 | |||
| (€413 - €484) | (-0.024 - -0.009) | (€0 - €0) | (-0.005 - -0.001) | ||||
| Disease free | € 22,059 | 11.702 | 9.346 | € 20,629 | 10.173 | 8.115 | |
| (€14,672 - €26,780) | (3.664 - 15.601) | (2.861 - 12.575) | (€13,818 - €25,232) | (2.978 - 14.200) | (2.301 - 11.416) | ||
| Local recurrence | € 9,334 | 0.901 | 0.643 | € 7,532 | 0.720 | 0.514 | |
| (€0 - €50,138) | (0.000 - 4.453) | (0.000 - 3.193) | (€0 - €40,739) | (0.000 - 3.627) | (0.000 - 2.624) | ||
| Distant metastases | € 180,314 | 6.576 | 3.958 | € 211,496 | 7.438 | 4.476 | |
| (€51,054 - €408,389) | (2.284 - 12.167) | (1.349 - 7.429) | (€67,569 - €455,225) | (2.849 - 12.974) | (1.705 - 7.954) | ||
| Total | € 243,216 | 19.180 | 13.930 | € 239,657 | 18.331 | 13.103 | |
| (€107,224 - €491,079) | (16.425 - 21.668) | (11.705 - 15.891) | (€91,498 - €497,968) | (15.264 - 21.112) | (10.769 - 15.239) | ||
| Guideline scenario | |||||||
| Trastuzumab treatmenta | € 31,376 | € 0 | |||||
| (€29,565 - €33,271) | (€0 - €0) | ||||||
| Cardiac event / monitoring | € 449 | -0.016 | € 0 | -0.003 | |||
| (€415 - €485) | (-0.024 - -0.010) | (€0 - €0) | (-0.005 - -0.001) | ||||
| Disease free | € 22,398 | 12.045 | 9.618 | € 20,907 | 10.447 | 8.332 | |
| (€20,052 - €25,169) | (10.611 - 13.492) | (8.387 - 10.878) | (€18,411 - €23,677) | (8.486 - 12.186) | (6.731 - 9.776) | ||
| Local recurrence | € 3,236 | 0.334 | 0.238 | € 2,338 | 0.246 | 0.175 | |
| (€78 - €12,343) | (0.006 - 1.226) | (0.005 - 0.874) | (€44 - €9,687) | (0.004 – 1.000) | (0.003 - 0.719) | ||
| Distant metastases | € 166,984 | 6.132 | 3.688 | € 195,703 | 6.921 | 4.162 | |
| (€66,592 - €318,118) | (2.967 - 9.186) | (1.757 - 5.631) | (€78,795 - €377,394) | (3.347 - 10.475) | (1.963 - 6.449) | ||
| Total | € 224,443 | 18.511 | 13.527 | € 218,948 | 17.613 | 12.666 | |
| (€124094 - €376,989) | (15.543 - 21.252) | (11.651 - 15.381) | (€102,933 - €400,182) | (14.357 - 20.644) | (10.593 - 14.715) | ||
| Trastuzumab Costs (95% CI) |
No Trastuzumab | |||||||
|---|---|---|---|---|---|---|---|---|
| Lys (95% CI) |
QALYs (95% CI) |
Costs (95%) |
Lys (95% CI) |
QALYs (95% CI) |
||||
| Trial scenario | ||||||||
| Trastuzumab treatmenta | € 30,564 | € 0 | ||||||
| (€28,753 - €32,478) | (€0 - €0) | |||||||
| Cardiac event / monitoring | € 439 | -0.004 | € 0 | -0.001 | ||||
| (€405 - €474) | (-0.006 - -0.003) | (€0 - €0) | (-0.001 - 0.000) | |||||
| Disease free | € 22,078 | 12.172 | 9.723 | € 19,776 | 9.996 | 7.974 | ||
| (€19,794 - €24,774) | (11.022 - 13.358) | (8.714 - 10.787) | (€17,319 - €22,551) | (8.199 - 11.718) | (6.507 - 9.405) | |||
| Local recurrence | € 0 | 0.000 | 0.000 | € 0 | 0.000 | 0.000 | ||
| (€0 - €0) | (0.000 - 0.000) | (0.000 - 0.000) | (€0 - €0) | (0.000 - 0.000) | (0.000 - 0.000) | |||
| Distant metastases | € 200,585 | 7.275 | 4.379 | € 245,341 | 8.523 | 5.131 | ||
| (€117,747 - €337,277) | (6.022 - 8.497) | (3.429 - 5.358) | (€140,871 - €416,862) | (6.778 - 10.307) | (3.883 - 6.485) | |||
| Total | € 253,666 | 19.448 | 14.098 | € 265,116 | 18.519 | 13.104 | ||
| (€170,975 - €389,649) | (18.992 - 19.892) | (13.223 - 14.933) | (€160,895 - €437,653) | (17.515 - 19.308) | (12.009 - 14.145) | |||
| Incremental analyses | |||||||
|---|---|---|---|---|---|---|---|
| Trastuzumab | No trastuzumab | Increment | ICER | ||||
| Costs | QALYs | Costs | QALYs | Costs | QALYs | ||
| Real world scenario | € 243,216 | 13.930 | € 239,657 | 13.103 | € 3,560 | 0.827 | € 4,304 |
| Guideline scenario | € 224,443 | 13.527 | € 218,948 | 12.666 | € 5,495 | 0.861 | € 6,382 |
| Trial scenario | € 253,666 | 14.098 | € 265,116 | 13.104 | -€11,451 | 0.993 | Dominance |
0aTrastuzumab treatment costs includes HER2 testing costs